Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp.'s filings document financial results and operating disclosures for a genomics diagnostics company focused on rare disease testing. Form 8-K reports furnish quarterly and annual results, earnings presentations, preliminary revenue and testing-volume guidance, changes in statement presentation, and modifications to non-GAAP financial measure methodology.
The filing record also covers capital structure and governance matters, including a term loan agreement used to refinance existing debt, Class A common stock and Nasdaq-listed warrant disclosures, board composition changes, and definitive proxy materials. Proxy filings describe director elections, executive compensation, equity awards, stockholder voting matters, and related corporate governance policies.
GeneDx Holdings Corp. (WGS) reported that its chief executive officer, Katherine Stueland, had 6,547 Restricted Stock Units settle into the same number of shares of Class A Common Stock on September 9, 2026. Of these shares, 3,692 were sold in a broker-assisted "sell to cover" transaction at a weighted average price of $84.22 per share to satisfy tax withholding obligations and were not a discretionary sale. After this tax-related sale, she beneficially owned 107,227 shares of Class A Common Stock, held RSUs for up to 298,978 additional shares, and options to purchase up to 107,610 shares, all vesting according to their respective terms.
GeneDx Holdings Corp. (WGS) reported that Chief Financial Officer Kevin Feeley settled 2,462 Restricted Stock Units into an equal number of shares of Class A Common Stock on September 9, 2026. On the same day, he sold 1,285 shares in a sell-to-cover transaction at a weighted average price of $84.2179 per share to satisfy tax withholding obligations, which the company states was not a discretionary trade. Following this sale, he beneficially owned 41,476 shares of Class A Common Stock and held RSUs for up to 78,864 shares and options for up to 25,906 shares, all vesting according to their terms.
GeneDx Holdings Corp. (WGS) reported that its Chief Financial Officer, Kevin Feeley, settled 717 Restricted Stock Units into 717 shares of Class A Common Stock on September 1, 2026, for no cash consideration. On the same date, 372 of those shares were sold at a weighted average price of $83.839 per share solely to satisfy tax withholding obligations in a non-discretionary “sell to cover” transaction. After these events, Feeley beneficially owned 40,299 shares of Class A Common Stock, RSUs for up to 81,326 additional shares, and options for up to 25,906 shares, all vesting according to their existing terms.
GeneDx Holdings Corp. (WGS) received a notice that officer Kevin Feeley has filed to sell up to 5,410 shares of Class A common stock under Rule 144 through Morgan Stanley Smith Barney, with an approximate sale date of September 1, 2026 on NASDAQ.
The shares relate to anticipated vesting of restricted stock units in three tranches of 372, 1,284, and 3,754 shares in September 2026. Feeley previously sold 5,364 shares during June 2026 to cover tax withholding obligations from RSU vesting.
GeneDx Holdings Corp. (WGS) received a notice that reporting person Katherine Stueland plans to sell 14,243 shares of Class A common stock under Rule 144 through Morgan Stanley Smith Barney on NASDAQ. The planned sale relates to anticipated vesting of 3,686 RSU shares on September 9, 2026 and 10,557 RSU shares on September 16, 2026. Over the past three months, Stueland sold 14,140 shares of Class A common stock to cover tax withholding obligations from RSU vesting.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of Class A common stock of GENEDX HOLDINGS CORP. They report aggregate beneficial ownership of 1,733,592.38 shares, representing 5.8% of the class.
Both entities report 0 shares with sole voting and dispositive power and 1,733,499.38 shares with shared voting power and 1,733,509.38 shares with shared dispositive power. Ownership is reported by GS Group as a parent holding company, with the securities owned or deemed owned by Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser. The Goldman Sachs reporting units disclaim beneficial ownership in certain client accounts and investment entities as described.
GeneDx Holdings Corp. (WGS) received an amended Schedule 13G filing reporting that ARK Investment Management LLC and its CEO/CIO Catherine D. Wood beneficially own 1,581,810 shares of GeneDx common stock, representing 5.33% of the class.
ARK reports sole voting power over 1,493,030 shares and shared voting power over 22,855 shares. ARK has sole dispositive power over 1,581,810 shares. Catherine D. Wood reports shared voting power over 1,515,885 shares and shared dispositive power over 1,581,810 shares.
GeneDx Holdings Corp. reported second quarter 2026 revenue of $114.4 million, up 11% year-over-year, with exome and genome test revenue of $100.3 million, up 17%. Exome and genome volume rose 32% to 30,785 tests, reflecting strong demand across geneticists, pediatric neurology and NICU.
Profitability remained mixed. The company generated adjusted gross margin of about 70% and adjusted net income of $0.4 million, but recorded a GAAP net loss of $17.7 million for the quarter and a net loss of $81.056 million for the first half of 2026. GAAP gross margin was 68%.
Cash, cash equivalents, marketable securities and restricted cash totaled $133.5 million as of June 30, 2026. GeneDx amended and restated its loan agreement with Blackstone, adding a $50.0 million term loan facility that raises total facility capacity to $150.0 million and is paired with a $5.0 million equity investment, resulting in a pro forma cash position of approximately $188 million. Management reaffirmed full-year 2026 guidance, including revenue of $475–$490 million, at least 30% exome and genome volume growth, approximately 70% adjusted gross margin and positive adjusted net income, and guided Q3 2026 revenue to $122–$124 million with adjusted net income of about $2 million.
BlackRock, Inc. filed as a significant shareholder of GeneDx Holdings Corp., reporting beneficial ownership of 1,622,518 shares of Class A stock, representing 5.5% of the class. BlackRock reports sole voting power over 1,588,670 shares and sole dispositive power over 1,622,518 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of GeneDx’s outstanding common shares.